A drug studied by gastroenterologists at the University of Michigan Health System may offer relief for symptoms of irritable bowel syndrome. In clinical trials patients showed improvement in abdominal pain and discomfort, cramping and bloating.
A new combination of investigational drugs successfully suppressed hepatitis C genotype 1 infection in a high percent of patients who had not responded to previous treatment in a study led by a University of Michigan hepatologist.
Reporters, producers and editors, here is our holiday gift to you: Story ideas that relate to the holidays, and some evergreen ideas that can help you fill the newspaper or broadcast during the slow news month ahead.
Liver transplantation candidates want to be involved in decisions regarding quality of the donor organ, and many are reluctant to accept organs with a higher risk of failure, according to research by U-M physicians and experts.
U-M defeated Ohio State twice this week, even before taking the field for the big game, signing up more people to the state's organ donor list and collecting more pints of blood in two annual challenges.
A rebound of the Hepatitis B virus is common in patients receiving nucleoside analogs for chronic hepatitis but nearly 40% of the rebounds or virological breakthroughs (VBTs) were not related to antiviral drug resistance.
Millions of people in the United States suffer from irritable bowel syndrome, but new research indicates a drug therapy could offer long-lasting relief. William Chey, M.D., professor in the Department of Internal Medicine was among the researchers who studied the drug rifaximin's effects on IBS patients. The research will be published in the New England Journal of Medicine Jan. 6.